Annual CFF
$361.14 M
+$2.51 B+116.81%
December 31, 2024
Summary
- As of February 26, 2025, RPRX annual cash flow from financing activities is $361.14 million, with the most recent change of +$2.51 billion (+116.81%) on December 31, 2024.
- During the last 3 years, RPRX annual CFF has fallen by -$23.97 million (-6.22%).
- RPRX annual CFF is now -75.72% below its all-time high of $1.49 billion, reached on December 31, 2020.
Performance
RPRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$257.96 M
+$67.54 M+20.75%
December 31, 2024
Summary
- As of February 26, 2025, RPRX quarterly cash flow from financing activities is -$257.96 million, with the most recent change of +$67.54 million (+20.75%) on December 31, 2024.
- Over the past year, RPRX quarterly CFF has dropped by -$26.07 million (-11.24%).
- RPRX quarterly CFF is now -116.33% below its all-time high of $1.58 billion, reached on June 30, 2020.
Performance
RPRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$361.14 M
-$26.07 M-6.73%
December 31, 2024
Summary
- As of February 26, 2025, RPRX TTM cash flow from financing activities is $361.14 million, with the most recent change of -$26.07 million (-6.73%) on December 31, 2024.
- Over the past year, RPRX TTM CFF has increased by +$2.51 billion (+116.81%).
- RPRX TTM CFF is now -76.78% below its all-time high of $1.56 billion, reached on June 30, 2020.
Performance
RPRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RPRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +116.8% | -11.2% | +116.8% |
| 3 y3 years | -6.2% | -11.2% | +116.8% |
| 5 y5 years | +130.3% | -11.2% | +116.8% |
RPRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -6.2% | +116.8% | -122.3% | +81.0% | -7.6% | +116.5% |
| 5 y | 5-year | -75.7% | +116.8% | -116.3% | +81.0% | -76.8% | +116.5% |
| alltime | all time | -75.7% | +116.8% | -116.3% | +81.0% | -76.8% | +116.5% |
Royalty Pharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $361.14 M(-116.8%) | -$257.96 M(-20.7%) | $361.14 M(-6.7%) |
| Sep 2024 | - | -$325.50 M(-128.1%) | $387.21 M(-159.9%) |
| Jun 2024 | - | $1.16 B(-645.6%) | -$646.77 M(-69.9%) |
| Mar 2024 | - | -$212.00 M(-8.6%) | -$2.15 B(+0.1%) |
| Dec 2023 | -$2.15 B(+127.4%) | -$231.89 M(-82.9%) | -$2.15 B(-1.5%) |
| Sep 2023 | - | -$1.36 B(+291.8%) | -$2.18 B(+107.3%) |
| Jun 2023 | - | -$347.00 M(+64.9%) | -$1.05 B(+12.7%) |
| Mar 2023 | - | -$210.37 M(-20.8%) | -$934.26 M(-1.1%) |
| Dec 2022 | -$944.86 M(-345.3%) | -$265.55 M(+15.4%) | -$944.86 M(+7.7%) |
| Sep 2022 | - | -$230.09 M(+0.8%) | -$877.38 M(-326.7%) |
| Jun 2022 | - | -$228.25 M(+3.3%) | $386.98 M(-1.0%) |
| Mar 2022 | - | -$220.97 M(+11.6%) | $390.82 M(+1.5%) |
| Dec 2021 | $385.11 M | -$198.07 M(-119.2%) | $385.11 M(+25.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $1.03 B(-560.9%) | $305.79 M(-128.2%) |
| Jun 2021 | - | -$224.41 M(-1.0%) | -$1.09 B(-251.2%) |
| Mar 2021 | - | -$226.67 M(-18.3%) | $717.98 M(-51.7%) |
| Dec 2020 | $1.49 B(-224.8%) | -$277.39 M(-22.4%) | $1.49 B(+0.6%) |
| Sep 2020 | - | -$357.39 M(-122.6%) | $1.48 B(-4.9%) |
| Jun 2020 | - | $1.58 B(+191.1%) | $1.56 B(-565.5%) |
| Mar 2020 | - | $542.52 M(-289.8%) | -$334.15 M(-72.0%) |
| Dec 2019 | -$1.19 B(-13.6%) | -$285.80 M(+1.8%) | -$1.19 B(+31.6%) |
| Sep 2019 | - | -$280.69 M(-9.5%) | -$905.82 M(+44.9%) |
| Jun 2019 | - | -$310.18 M(-1.5%) | -$625.13 M(+98.5%) |
| Mar 2019 | - | -$314.96 M | -$314.96 M |
| Dec 2018 | -$1.38 B(+1018.9%) | - | - |
| Dec 2017 | -$123.25 M | - | - |
FAQ
- What is Royalty Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for Royalty Pharma?
- What is Royalty Pharma annual CFF year-on-year change?
- What is Royalty Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Royalty Pharma?
- What is Royalty Pharma quarterly CFF year-on-year change?
- What is Royalty Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Royalty Pharma?
- What is Royalty Pharma TTM CFF year-on-year change?
What is Royalty Pharma annual cash flow from financing activities?
The current annual CFF of RPRX is $361.14 M
What is the all time high annual CFF for Royalty Pharma?
Royalty Pharma all-time high annual cash flow from financing activities is $1.49 B
What is Royalty Pharma annual CFF year-on-year change?
Over the past year, RPRX annual cash flow from financing activities has changed by +$2.51 B (+116.81%)
What is Royalty Pharma quarterly cash flow from financing activities?
The current quarterly CFF of RPRX is -$257.96 M
What is the all time high quarterly CFF for Royalty Pharma?
Royalty Pharma all-time high quarterly cash flow from financing activities is $1.58 B
What is Royalty Pharma quarterly CFF year-on-year change?
Over the past year, RPRX quarterly cash flow from financing activities has changed by -$26.07 M (-11.24%)
What is Royalty Pharma TTM cash flow from financing activities?
The current TTM CFF of RPRX is $361.14 M
What is the all time high TTM CFF for Royalty Pharma?
Royalty Pharma all-time high TTM cash flow from financing activities is $1.56 B
What is Royalty Pharma TTM CFF year-on-year change?
Over the past year, RPRX TTM cash flow from financing activities has changed by +$2.51 B (+116.81%)